Limits...
A redesigned follitropin alfa pen injector for infertility: results of a market research study.

Abbotts C, Salgado-Braga C, Audibert-Gros C - Patient Prefer Adherence (2011)

Bottom Line: Most (88%, n = 64) patients found it easy to learn how to use the pen.Based on ease of teaching, 68% (n = 19) of nurses would choose to teach the pen in preference to any other injection method.Almost all (93%, n = 26) nurses considered that having the same pen format for a range of injectable gonadotropins would facilitate teaching and learning self-injection.

View Article: PubMed Central - PubMed

Affiliation: Pharmaceutical Marketing Research Consultancy, London, UK;

ABSTRACT

Background: The purpose of this study was to evaluate patient-learning and nurse-teaching experiences when using a redesigned prefilled, ready-to-use follitropin alfa pen injector.

Methods: Seventy-three UK women of reproductive age either administering daily treatment with self-injectable gonadotropins or about to start gonadotropin treatment for infertility (aged 24-47 years; 53 self-injection-experienced and 20 self-injection-naïve) and 28 nurses from UK infertility clinics were recruited for the study. Following instruction, patients and nurses used the redesigned follitropin alfa pen to inject water into an orange and completed questionnaires to evaluate their experiences with the pen immediately after the simulated injections.

Results: Most (88%, n = 64) patients found it easy to learn how to use the pen. Among injection-experienced patients, 66% (n = 35) agreed that the redesigned pen was easier to learn to use compared with their current method and 70% (n = 37) also said they would prefer its use over current devices for all injectable fertility medications. All nurses considered the redesigned pen easy to learn and believed it would be easy to teach patients how to use. Eighty-six percent (n = 24) of the nurses thought it was easy to teach patients to determine the remaining dose to be dialed and injected in a second pen if the initial dose was incomplete. Compared with other injection devices, 96% (n = 27) thought it was "much easier" to "as easy" to teach patients to use the redesigned pen. Based on ease of teaching, 68% (n = 19) of nurses would choose to teach the pen in preference to any other injection method. Almost all (93%, n = 26) nurses considered that having the same pen format for a range of injectable gonadotropins would facilitate teaching and learning self-injection.

Conclusion: In this market research study with infertile patients and infertility nurses, the redesigned follitropin alfa pen was perceived as easy to learn, easy to teach how to use, and well accepted.

No MeSH data available.


Related in: MedlinePlus

The components of the redesigned follitropin alfa pen injector: 1, dose-setting knob; 2, dose display; 3, plunger piston; 4, graduated reservoir holder; 5, threaded needle connector; 6, pen cap; 7, removable needle; 8, inner needle shield; 9, outer needle cap; 10, peel-off seal tab. The pen barrel and cartridge comprise sections 1–5.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC3140313&req=5

f1-ppa-5-315: The components of the redesigned follitropin alfa pen injector: 1, dose-setting knob; 2, dose display; 3, plunger piston; 4, graduated reservoir holder; 5, threaded needle connector; 6, pen cap; 7, removable needle; 8, inner needle shield; 9, outer needle cap; 10, peel-off seal tab. The pen barrel and cartridge comprise sections 1–5.

Mentions: Patient-learning and nurse-teaching experiences when using the redesigned follitropin alfa prefilled pen (GONAL-f ®/GONAL-f ® Revised Formulation Female Prefilled Pen, Merck Serono SA, Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, Figure 1) were evaluated in this market research study. Before a moderator presented and demonstrated the operation of the pen injector to the nurses, they completed part of an online nurses’ questionnaire (Appendix 1) pertaining to use and perceptions of existing devices for administering fertility treatment. To ensure consistent demonstration of the pen injector, the moderator followed a script that outlined step-by-step written and diagrammatic instructions. This was also available to nurses as additional guidance in handling the pen. After receiving the verbal and written instructions, nurses were each given a new, unbranded 900 IU demonstration pen, prefilled with water for injection, and were asked to attach the needle, practice removing large air bubbles, and inject 125 IU of water into an orange as many times as required to gain familiarity with the pen injector. Nurses then completed the part of the nurses’ questionnaire on ease of learning. The nurses then repeated the process, training small groups of up to five patients per nurse. The moderator ensured that an accurate demonstration of the pen injector was provided to patients.


A redesigned follitropin alfa pen injector for infertility: results of a market research study.

Abbotts C, Salgado-Braga C, Audibert-Gros C - Patient Prefer Adherence (2011)

The components of the redesigned follitropin alfa pen injector: 1, dose-setting knob; 2, dose display; 3, plunger piston; 4, graduated reservoir holder; 5, threaded needle connector; 6, pen cap; 7, removable needle; 8, inner needle shield; 9, outer needle cap; 10, peel-off seal tab. The pen barrel and cartridge comprise sections 1–5.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC3140313&req=5

f1-ppa-5-315: The components of the redesigned follitropin alfa pen injector: 1, dose-setting knob; 2, dose display; 3, plunger piston; 4, graduated reservoir holder; 5, threaded needle connector; 6, pen cap; 7, removable needle; 8, inner needle shield; 9, outer needle cap; 10, peel-off seal tab. The pen barrel and cartridge comprise sections 1–5.
Mentions: Patient-learning and nurse-teaching experiences when using the redesigned follitropin alfa prefilled pen (GONAL-f ®/GONAL-f ® Revised Formulation Female Prefilled Pen, Merck Serono SA, Geneva, Switzerland, an affiliate of Merck KGaA, Darmstadt, Germany, Figure 1) were evaluated in this market research study. Before a moderator presented and demonstrated the operation of the pen injector to the nurses, they completed part of an online nurses’ questionnaire (Appendix 1) pertaining to use and perceptions of existing devices for administering fertility treatment. To ensure consistent demonstration of the pen injector, the moderator followed a script that outlined step-by-step written and diagrammatic instructions. This was also available to nurses as additional guidance in handling the pen. After receiving the verbal and written instructions, nurses were each given a new, unbranded 900 IU demonstration pen, prefilled with water for injection, and were asked to attach the needle, practice removing large air bubbles, and inject 125 IU of water into an orange as many times as required to gain familiarity with the pen injector. Nurses then completed the part of the nurses’ questionnaire on ease of learning. The nurses then repeated the process, training small groups of up to five patients per nurse. The moderator ensured that an accurate demonstration of the pen injector was provided to patients.

Bottom Line: Most (88%, n = 64) patients found it easy to learn how to use the pen.Based on ease of teaching, 68% (n = 19) of nurses would choose to teach the pen in preference to any other injection method.Almost all (93%, n = 26) nurses considered that having the same pen format for a range of injectable gonadotropins would facilitate teaching and learning self-injection.

View Article: PubMed Central - PubMed

Affiliation: Pharmaceutical Marketing Research Consultancy, London, UK;

ABSTRACT

Background: The purpose of this study was to evaluate patient-learning and nurse-teaching experiences when using a redesigned prefilled, ready-to-use follitropin alfa pen injector.

Methods: Seventy-three UK women of reproductive age either administering daily treatment with self-injectable gonadotropins or about to start gonadotropin treatment for infertility (aged 24-47 years; 53 self-injection-experienced and 20 self-injection-naïve) and 28 nurses from UK infertility clinics were recruited for the study. Following instruction, patients and nurses used the redesigned follitropin alfa pen to inject water into an orange and completed questionnaires to evaluate their experiences with the pen immediately after the simulated injections.

Results: Most (88%, n = 64) patients found it easy to learn how to use the pen. Among injection-experienced patients, 66% (n = 35) agreed that the redesigned pen was easier to learn to use compared with their current method and 70% (n = 37) also said they would prefer its use over current devices for all injectable fertility medications. All nurses considered the redesigned pen easy to learn and believed it would be easy to teach patients how to use. Eighty-six percent (n = 24) of the nurses thought it was easy to teach patients to determine the remaining dose to be dialed and injected in a second pen if the initial dose was incomplete. Compared with other injection devices, 96% (n = 27) thought it was "much easier" to "as easy" to teach patients to use the redesigned pen. Based on ease of teaching, 68% (n = 19) of nurses would choose to teach the pen in preference to any other injection method. Almost all (93%, n = 26) nurses considered that having the same pen format for a range of injectable gonadotropins would facilitate teaching and learning self-injection.

Conclusion: In this market research study with infertile patients and infertility nurses, the redesigned follitropin alfa pen was perceived as easy to learn, easy to teach how to use, and well accepted.

No MeSH data available.


Related in: MedlinePlus